In recent years, the introduction of immune checkpoint inhibitors to the oncolytic pipeline has been a significant breakthrough in cancer treatment, but unfortunately some tumors respond only minimally. Besides CTLA-4, and since the approval of PD-1/PD-L1 inhibitors, only the anti-LAG3 strategy (relatlimab, Bristol Myers Squibb Co.) has been good enough to reach the market. In a session dealing with emerging checkpoints beyond PD-1, CTLA-4 and LAG3, Drew Rasco from the START Center for Cancer Care depicted a new player on the ground of immunotherapeutic options.
Sookmyung Women’s University has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and fibrosis.
Beigene Ltd. has divulged 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H)-one derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Insilico Medicine IP Ltd. has identified heteroaromatic compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Duality Biologics (Suzhou) Co. Ltd. has synthesized antibody-drug conjugates comprising anti-GPC3 antibodies covalently linked to exatecan derivatives through a linker. They are reported to be useful for the treatment of cancer.
Biotheryx Inc. has disclosed PROTAC compounds comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to a SOS1 targeting moiety via linker.
Sotio Biotech AS, a company owned by PPF Group, has entered into a license and option agreement with Synaffix BV, a Lonza company, to develop next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors.
At the AACR-NCI-EORTC meeting in Boston, Aurigene Oncology Ltd. reported their research on paralogue selective degraders of SMARCA2 (AU-SM2-1) and SMARCA4 (AU-SM4-1).
RSS
